Ischemia Care (ISC) is commercial stage, venture backed, molecular diagnostic company commercializing blood tests for cause of stroke, including atrial fibrillation; across the stroke care continuum, including point of care. In 2019, launched its first test, ISCDX, through a company owned division called, Ischemic Stroke Lab.
ISCDX is offered as an “in hospital” test, as a CLIA LDT, a priced at $1500, results are reported while the patient is hospitalized, and paid for out of the hospital DRG proceeds. The testing is offered in conjunction with Ischemia Care’s proprietary hospital cost effectiveness program.
In addition to diagnostic testing, ISC’s service offerings target pharma and device companies to apply biomarkers, personalized medicine, health care economics, and data analytics to create new sales channels for these companies.
ISC conducted the BASE clinical trial (NCT02014896), that recruited over 1700 subjects and is the most successful stroke biomarker clinical trial ever conducted, demonstrating significant clinical support. BASE also created an network into over 20 major comprehensive stroke centers, with each CSC representing up to 26 hospitals in the geographic area.
ISC intellectual property is based upon 15 years of peer reviewed published research and is the first to demonstrate RNA expression may be used to determine cause of stroke. Additionally, ISC has developed proprietary laboratory methodology and analysis methodology that is employed in the company CLIA laboratory.